Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|217721-2MG||Glass bottle||2 mg||
|Overview||A cell-permeable quinolinyl thiazolinone compound that acts as a potent and ATP-competitive inhibitor of Cdk1 (Ki = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively). It affects Cdk2/E, PKCδ, and SGK only at much higher concentrations (Ki = 340, 318, and 497 nM, respectively), and shows little effect against Cdk4/D and six other commonly studied kinases (Ki =2 µM). Short-term treatment for up to 20 hrs results in fully reversible G2/M cell cycle arrest, while prolonged treament (>48 hrs) results in apoptotic cell death in proliferating cancer cells, but not in nontumorigenic epithelial cell lines. The solid form of this compound (Cat. No. 217699) is also available.|
|References||Vassilev, L.T., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 10660.|
|Formulation||A 10 mM (2 mg/569 µL) solution of Cdk1 Inhibitor IV, RO-3306 (Cat. No. 217699) in DMSO.|
|Structure formula Image|
|Primary Target||Cdk1/B1 and Cdk1/A|
|Primary Target K<sub>i</sub>||35 nM and 110 nM for Cdk1/B1 and Cdk1/A,|
|Secondary target||Cdk2/E, PKCδ, and SGK|
|Purity||≥95% by HPLC|
|Safety Information according to GHS|
|R Phrase||R: 36/38
Irritating to eyes and skin.
|S Phrase||S: 26-36
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing.
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Vassilev, L.T., et al. 2006. Proc. Natl. Acad. Sci. USA 103, 10660.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.